Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Immunol. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
PMCID: PMC2923839

mTOR Inhibition and Alloantigen-Specific Regulatory T Cells Synergize to Promote Long-Term Graft Survival in Immunocompetent Recipients1


Minimization of immunosuppression and donor-specific tolerance to MHC-mismatched organ grafts are important clinical goals. The therapeutic potential of regulatory T cells (Treg) has been demonstrated, but conditions for optimizing their in vivo function post-transplant in nonlymphocyte-depleted hosts remain undefined. Herein, we address mechanisms through which inhibition of the mammalian target of rapamycin (Rapa) (mTOR) synergizes with alloAg-specific Treg (AAsTreg), to permit long-term, donor-specific heart graft survival in immunocompetent hosts. Crucially, immature allogeneic dendritic cells (DC) allowed AAsTreg selection in vitro, with minimal expansion of unwanted (TH17) cells. The rendered Treg potently inhibited T cell proliferation in an Ag-specific manner. However, these AAsTreg remained unable to control T cells stimulated by allogeneic mature DC, – a phenomenon dependent on the release of pro-inflammatory cytokines. In vivo, Rapa administration reduced danger-associated IL-6 production, T cell proliferation and graft infiltration. Based on these observation, AAsTreg were administered post-transplant (d7) in combination with a short course of Rapa and rendered >80% long-term (>150 d) graft survival, a result superior to that achieved with polyclonal Treg. Moreover, graft protection was alloAg-specific. Significantly, long-term graft survival was associated with alloreactive T cell anergy. These findings delineate combination of transient mTOR inhibition with appropriate AAsTreg selection as an effective approach to promote long-term organ graft survival.


The ability to induce donor-specific tolerance in organ transplantation would obviate allograft rejection and patients’ dependency on life-long immunosuppressive drug therapy (1). Currently, there is considerable interest in developing cell-based therapies that promote tolerance induction in experimental models (2, 3), and that provide a feasible approach to achieving this goal in humans. Thus, the suppressive activity of naturally-occurring regulatory T cells (Treg)3, necessary to control immune reactivity and prevent autoimmunity, has captured considerable attention (47), since before the availability of markers by which to specifically purify Treg (8). Extensive studies in animal models and screening of patients have established the importance of Treg in the control of allograft rejection (9, 10) and other inflammatory or immune-mediated disorders (1113). Moreover, early clinical reports suggest a correlation between organ graft survival and circulating Treg function (14). Polyclonal Treg have been used successfully to prevent rejection responses in rodents. However, antigen (Ag)-specific Treg (commonly obtained from TCR transgenic mice) have proved more powerful, with the added benefit of minimizing suppression of unrelated responses (4, 5, 15) Additionally, several groups have shown that, following their isolation from normal, unmanipulated hosts, Treg can be expanded in culture with appropriate specificity, then adoptively transferred to suppress organ or bone marrow allograft rejection (1618).

To date, the capacity of adoptively-transferred Treg to promote MHC-incompatible organ graft survival in rodents has been demonstrated only in immunologically-impaired hosts,- either T- and B cell-deficient (RAG−/−) (19), T cell-depleted (20), or irradiated animals (17). Additionally, the approach employed in most of these models has involved the injection of Treg before transplantation, precluding application to deceased donor transplantation. These limitations can be rationalized by the need to harness multiple mechanisms encompassing deletion, anergy, and regulation (21) to establish a robust state of tolerance, an outcome difficult to obtain with a single infusion of Treg. Moreover, recent findings suggest that the suppressive activity of Treg is diminished by danger signal-mediated maturation of antigen(Ag)-presenting cells (APC),- an effect mediated by a still poorly-defined cocktail of cytokines (22, 23). Although the influence of these cytokines on Ag-specific Treg is unknown, it is reasonable to speculate that, in unmanipulated graft recipients the combination of pro-inflammatory cytokines released following surgery (24), and the activation of large numbers of effector T cells in response to transplantation, may override the protective ability of Treg (endogenous and exogenous). An additional factor that limits Treg function is the capacity of calcineurin inhibitors (cyclosporine A or tacrolimus), used to prevent acute rejection, to block the pro-tolerogenic activity of Treg. By contrast, inhibition of the mammalian target of rapamycin (mTOR), a downstream target of PI3K/Akt signaling, spares the induction of transplant tolerance (2527). Moreover, CD4+CD25+ Treg are relatively resistant to the rapamycin (Rapa) (28, 29) and can expand in its presence (6, 2931).

Isolation of comparatively pure human Treg is difficult due to the lack of Treg–specific markers. We have recently developed a purification strategy based on differential expression of the co-regulatory molecule programmed cell death-1 (PD-1) that allows distinction between Treg and activated T cells (30). Additionally, an alternative strategy based on reduced expression of CD127 (IL-7R) on Treg has been proposed (32, 33). Availability of these strategies renders the therapeutic use of Treg a potential clinical reality and urges the identification of a protocol that would exploit and support their therapeutic capacity.

We report herein that co-culture of Treg with immature, donor-derived DC in a conditioned medium is preferable over the use of mature DC, for the selection of potent allo-Ag-specific Treg (AAsTreg). We show also that the highly suppressive function of AAsTreg is susceptible to modulation by danger signal-induced DC maturation. However, post-transplant administration of Rapa creates conditions that favor the tolerance-promoting function of Treg. In particular, Rapa alters the relative proportions of effector and endogenous Treg in favor of the latter, and suppresses pro-inflammatory cytokines produced by activated DC. Small numbers of adoptively transferred AAsTreg induced long-term (>150 day), donor-specific heart allograft survival in unmanipulated recipients when given one week post-transplant, under cover of a short, post-operative course of low dose Rapa. Additionally, graft survival was associated with anergy induction in directly alloreactive host T cells. By combining a reliable method of AAsTreg enrichment with a treatment (mTOR inhibition) conducive to their protective function, we have identified a promising approach for the induction of long-term, donor-specific organ transplant survival, with minimal host manipulation/drug-based immunosuppression.



Eight- to 12-wk-old C57BL/10 (B10; H-2Kb), C3H/HeJ (C3H; H-2Kk) and BALB/c (H-2Kd) mice were purchased from The Jackson Laboratory and maintained in the SPF central animal facility of University of Pittsburgh School of Medicine. B6.SJL-Ptprca/BoyAiTac (B6.SJL; H-2Kb) were purchased from Taconic Farms. IL-6−/− C57BL/6 mice were a gift from Dr A.J. Demetris (Department of Pathology, University of Pittsburgh). Experiments were conducted under an institutional animal care and use committee-approved protocol and in accordance with National Institutes of Health-approved guidelines


Complete medium (CM) comprised RPMI-1640 (Gibco, Invitrogen, Carlsbad, CA) supplemented with 10% v/v FCS (Atlanta Biologicals, Lawrenceville, GA), non-essential amino acids, L-glutamine, sodium pyruvate, penicillin-streptomycin and 2-ME (all from Invitrogen, Carlsbad, CA). Anti-mouse IL-2, IFN-γ, IL-17, CD4, CD25, Glucocorticoid-Induced TNFR-Related (GITR) protein, CD62L, CTLA-4, CCR5, CD103, and Lag-3 mAbs were from BD PharMingen (San Diego, CA); Purified mouse CCL19-Fc (for detection of mouse CCR7) and anti-forkhead box P3 (Foxp3; clone FJK-16s) were purchased from eBioscience (San Diego, CA). Anti-CCR4 mAb was purchased from Capralogics (Hardwick, MA). Vybrant CFDA SE cell tracer kit was purchased from Molecular Probes (Invitrogen, Carlsbad, CA). Magnetic microbeads and separation columns were from Miltenyi (Miltenyi Biotec, Auburn, CA) or Invitrogen, as indicated.

T cells and Treg purification

T cells were purified from mouse spleens and lymph nodes using the following procedure. Single-cell suspensions were incubated with anti-CD11b, anti-CD8, anti-B220, anti-Gr-1, anti-CD16/32, anti-Ter119 (BD Bioscience, San Jose, CA), and anti-I-A/E (eBioscience, San Diego, CA) mAbs. Cells were washed and then incubated with anti-rat dynabeads (Dynal, Invitrogen) according to the manufacturer’s instructions. CD4+ cells were purified by magnetic negative selection. These represented “bulk” CD4+ T cells. For Treg isolation, bulk CD4+ T cells were incubated with anti-CD25-PE mAb, and CD4+CD25+ T cells isolated by positive selection using anti-PE microbeads and MS separation columns (Miltenyi Biotec). Purity was assessed by cytofluorometric analysis and was consistently 90–95%. The remaining cells were used as CD4+CD25 T cells for assays of suppressor function. For experiments on Foxp3 upregulation, the remaining CD4+CD25 T cells were depleted of residual CD25+ cells by depletion in AutoMACS automatic separator (Miltenyi Biotec) using the ‘depletionS’ program.

Generation of bone-marrow derived DC

Myeloid DC were propagated from bone marrow cells, as described (34). Briefly, femoral bone marrow was flushed with a PBS solution containing 2mM EDTA. Red blood cells were lysed and remaining cells plated in Petri dishes at 2×106/plate with recombinant (r)mGM-CSF (300 U/ml) and rmIL-4 (200 U/ml) (both from R&D systems, Minneapolis, MN). Media was changed every 3 days. On day 7, non-adherent cells were washed thoroughly and CD11c+ DC purified using anti-CD11c immunomagnetic beads and isolation columns (Miltenyi Biotec; manufacturer’s protocol). When indicated, mature DC were generated by adding LPS (200 ng/ml; E. coli K12; Invivogen, San Diego, CA) on d 6 of culture and harvesting the cells 24h later.

Generation of MLRsup

Bulk CD4+ T cells (B10) were co-cultured with mature allogeneic DC (BALB/c) at 20 T cells : 1 DC ratio. Cells were cultured in 96-well, round-bottom plates in 200 µl total volume/well of complete media at 37°C. After 5 d co-culture, supernatant was collected, centrifuged at 500×g for 5 min, filtered through 0.22µm filters, and stored at −80°C.

Quantification of Cytokines

MLRSup cytokine levels were assessed with the Luminex™ multiplexing platform (MiraiBio, Alameda, CA) using the BioSource 20-plex mouse cytokine bead set (BioSource-Invitrogen, San Diego, CA) and additional beadsets for the detection of IL-7, IL-9, IL-15, and IL-21 (Millipore), as per manufacturer's specifications. The concentration of active TGF-β1 in the MLRSup was determined using the Quantikine™ ELISA (R&D Systems, Inc., Minneapolis, MN), which detects the binding of active TGF-β1 to immobilized TGF-β1 type II receptors. The concentration of active TGF-β1 present in the supernatant was assessed after PBS treatment for 3 h in vitro according to the manufacturer's recommendation.

Enrichment of allo-Ag-specific Treg (AAsTreg) and phenotypic analysis

Freshly-isolated B10 Treg (CD4+CD25+) were incubated with allogeneic bone marrow-derived DC (BALB/c or C3H, depending on the experiment) at 3 Treg: 1 DC ratio in 96-well plates. Total volume per well was 150 µl, composed of 75 µl CM + 75 µl of MLRsup.. Human rIL-2 (a gift from Dr. M.T. Lotze, Department of Surgery, University of Pittsburgh; 500U/ml) was used instead of MLRsup where indicated. Cells were incubated at 37°C. After 5d co-culture, 50 µl/well of media was removed and replaced with 100µl of MLRsup (or CM + IL-2). On day 9–10, cells were collected and remaining DC removed by incubation with anti-CD11c-conjugated microbeads (Miltenyi Biotec) and AUTOMacs separation. The remaining cells (AAsTreg) were used for experimentation. To investigate the proliferation and cytokine release profile of Treg during co-culture, freshly-isolated Treg were CFSE stained with the Vybrant CFDA SE kit (Invitrogen; manufacturer’s protocol) before co-culture. After 5 d, cells were stained for marker expression or re-stimulated with PMA+Ionomycin for 5h and analyzed for intracellular expression of Foxp3 and the indicated cytokines (eBioscience; manufacturer’s staining protocol).

Suppressor assays

Graded numbers of γ-irradiated (2000 rad) BALB/c DC were used as stimulators of purified allogeneic (B10) bulk CD4 or CD4+CD25 T cells (2×105/well) in 72h MLR, using 96-well, round-bottom plates, as described (35). Titrated numbers of AAsTreg or freshly-isolated Treg were added where indicated. For the final 16–18h of culture, individual wells were pulse-labeled with 1 µCi [3H]thymidine. Radioisotope incorporation was determined using a beta scintillation counter. Results are expressed as mean cpm ± 1 SEM calculated from triplicate wells. To evaluate T cell proliferation in more detail, bulk B10 CD4 or CD4+CD25 T cells were CFSE-labeled. These CFSE+ T cells (2×105) were co-cultured with 2×104 allogeneic (C3H) DC in 96-well, round-bottom plates. The indicated numbers of AAsTreg or freshly-isolated Treg were added at the beginning of the culture. After 4–5 d, cells were collected and stained for surface CD4 and intracellular Foxp3. The CFSE dilution profile of CD4+Foxp3 T cells was then determined by flow cytometry.

In vivo Rapa treatment and IL-6 production by primary DC

B10 mice were treated for 10 d with daily i.p. injections of Flt3 ligand (Flt3L) to increase the number of DC in secondary lymphoid tissue (3638). Animals were separated into two groups based on the administration of Rapa (1mg/kg daily) during the last 7 d of FL treatment. On d 10, animals were euthanized and splenic DC purified by density gradient centrifugation followed by CD11c+ cells isolation. DC were then cultured overnight with or without LPS (1 µg/ml) and IL-6 released in the supernatant quantified by ELISA (ELISA Max, Biolegend, San Diego, CA).

Vascularized heart transplantation and AAsTreg administration

Heterotopic (intra-abdominal) heart transplantation was performed from BALB/c to B10 mice, as described (39). Groups of mice received a subtherapeutic regimen of 1 mg/kg/day i.p. Rapa (LC Laboratories, Woburn, MA) in a vehicle containing 0.02% Tween 80 and 0.26% polyethylene glycol (both from Sigma-Aldrich, St Louis, MO) for 10 consecutive days (d 0 to 9). Additional groups received either autologous, freshly-isolated Treg, AAsTreg (B10) enriched using BALB/c-derived DC, or AAsTreg (B10) enriched using C3H-derived DC. Transplant survival was assessed by daily transabdominal palpation. Rejection was defined by the complete cessation of cardiac contraction and confirmed histologically. Bulk CD4+ or CD4+CD25 T cells were purified from mice with long-surviving grafts (>150 d) or normal, age-matched mice. A fraction was analyzed for Foxp3 expression. The remaining cells were co-cultured with irradiated BALB/c-derived DC. Their proliferative response, in the presence or absence of rh IL-2 (100 U/ml), was assessed after 3d by thymidine incorporation, as described above.


Results are expressed as means ± 1 SEM. The significances of differences between means were determined using Student’s ‘t’ test. p < 0.05 was considered significant. Prism 5 Software package (GraphPad Software) was used to generate survival curves and the significance of differences in graft survival between groups was determined by Kaplan-Meier analysis and the log-rank test.


Alloreactive Treg are present in the pool of naturally-occurring Treg

The Ag specificity of naturally-occurring Treg remains a topic of intense investigation (4045). Although preliminary reports indicate that Treg can regulate alloreactive T cells, it remains unclear whether cells with specificity, or cross-reactivity (46), for alloAgs are present within the pool of naturally-occurring Treg. To confirm the presence of ‘alloreactive’ Treg, bulk CD4+ or CD4+CD25 T cells were purified from normal B10 mice and cultured in 3-day MLR with allogeneic (BALB/c) bone marrow-derived DC (alloDC). As shown in Fig. 1A, T cell proliferation increased significantly in the absence of Treg, suggesting the presence, in the CD4+CD25+ population, of cells able to suppress alloreactive T cell activation/expansion. To further characterize the behavior of Treg, we stained bulk CD4+ T cells with CFSE and co-cultured them with alloDC. Flow cytometric analysis of the CFSE dilution profile, in combination with Foxp3 staining (Fig. 1B), revealed that the buffering (suppressive) activity of Treg was associated with proliferation of a significant fraction of Foxp3+ cells (approximately 5% of the proliferating cells). To confirm that these Foxp3+ cells were derived from the pre-existing population of Treg, CFSE-stained CD4+CD25 T cells (Foxp3 confirmed by intracellular staining; data not shown) were stimulated with alloDC and the expression of Foxp3 quantified in proliferating cells after 4 days. Under these conditions, <1% of the proliferating cells showed upregulated Foxp3 (Fig. 1C). Interestingly, when congenic (CD45.1+) Treg were added back to the culture at physiological concentration (10% of CD4+ cells), but excluded from the analysis through appropriate gating strategy (Fig. 1D), approximately 2% of the proliferating CD4+ cells upregulated Foxp3. These results support the hypothesis that, although a fraction of effector T cells upregulates Foxp3 (and are possibly converted to induced Treg) in response to allo-stimulation, ‘alloreactive’ (or cross-reactive) cells are present in the Treg pool and are induced to proliferate extensively in MLR.

Figure 1
Treg comprise cells with alloAg specificity that control T cell alloreactivity

Selection of alloreactive Treg: mature DC induce IL-17+ allogeneic T cell expansion

A different outcome was obtained when purified CD4+CD25+ T cells (Treg) were co-cultured with allogeneic DC (Fig. 2A). By staining the purified population with CFSE before culture, then analyzing the dilution profile in combination with Foxp3 expression at d5, a reduced rate of proliferation in comparison to that seen with bulk CD4+ T cells was evident. The proliferating cells displayed an activated phenotype, as shown by up-regulation of surface Program Cell Death-1 (PD-1) (35), indicating that exposure to allogeneic DC induced their activation, but that factors able to fully sustain their expansion were absent. In an attempt to sustain their in vitro proliferation, CFSE-stained Treg were co-cultured with allogeneic DC matured by overnight exposure to LPS (47). Analysis of the CFSE dilution profile indicated increased proliferation of Foxp3+ cells (Fig. 2B); however, approximately 20% of the proliferating cells were Foxp3. To investigate the nature of these Foxp3 cells, CFSE-stained Treg were co-cultured with mature DC for 5 days, re-stimulated with PMA/ionomycin for 5 h, then analyzed for expression of IL-2, IFN-γ and IL-17 by intracellular staining (Fig. 2C). The results show that the Foxp3 cells were a heterogeneous population, including a major proportion of IL-17-producing (TH17) cells. As Yamazaki et al did not report this phenomenon (47), we tested whether the addition of exogenous IL-2, as used by these authors, could sustain Treg expansion and prevent Foxp3 T cell proliferation. We then repeated the same experiment in the presence of 500U/ml IL-2 (Fig. 2D). Unexpectedly, the exogenous IL-2 promoted Foxp3 TH17 cell proliferation even further. As TH17 cells have been characterized extensively as pro-inflammatory cells (48, 49), their expansion and the inability to separate them from (Foxp3+) Treg undermine the use of mature DC for selection of AAs Treg.

Figure 2
Co-culture of nTreg and mature DC favors the expansion of TH17 cells

MLRsup enhances Foxp3+ T cell expansion induced by immature DC

Our observation that Foxp3 cells were not obtained when Treg were incubated with immature DC (Fig. 2A) prompted us to explore an alternative approach to sustain alloreactive Treg expansion. Fig 1B indicates that during a MLR, Treg proliferate extensively. This suggests that a mixture of cytokines, probably produced by activated T cells, is released and sustains Treg expansion. We tested this hypothesis by adding a fraction of the supernatant obtained from MLR induced using bulk CD4+ T cells (MLRsup) to CFSE-stained Treg co-cultured with allogeneic immature DC. For comparative purposes, we added IL-2 (500U/ml) to some of the cultures. The resulting CFSE dilution profile (Fig 3) indicated that both approaches promoted strong expansion of Foxp3+ cells. Additionally, intracellular staining for IL-17 production in response to re-stimulation with PMA/ionomycin revealed the presence of a minimal proportion of TH17 cells, under both conditions. However, exogenous IL-2 yielded a significant proportion of proliferating Foxp3 T cells. As the suppressive ability of Treg is strictly linked to maintenance of Foxp3 expression (50, 51), we opted to use the combination of immature DC and MLRsup in subsequent alloreactive Treg selection procedures.

Figure 3
MLR supernatant (MLRSup) contains factors that stimulate the expansion of nTreg, preserve Foxp3 expression, and minimize TH17 cell proliferation

The difference between IL-2 and MLRsup underscored the presence in the latter of important factors that sustained the expression of Foxp3 during Treg proliferation. In an attempt to identify possible candidates, we quantified the cytokine content of the MLRsup using the Luminex™ multiplex platform and a 20-plex mouse cytokine bead set (BioSource-Invitrogen, San Diego, CA), with the addition of common γ-chain signaling cytokines (IL-7, -9, -15, and -21), and ELISA-based measurement of active TGF-β1 (Fig 3B). Surprisingly, the most obvious candidates (TGF-β1, IL-4, IL-7, IL-9, and IL-15) were present at extremely low or even undetectable levels, compromising our ability to identify the key mediators for sustained Foxp3 expression.

Selected Treg retain a regulatory phenotype and are alloAg-specific

Purified host-derived CD4+CD25+ T cells were cultured for 8–10 days with donor-derived immature DC in the presence of MLRsup (Fig. 4A). We then evaluated the characteristics of the resulting T cell population following immunomagnetic bead-based depletion of the remaining CD11c+ cells. The cells exhibited a conventional regulatory phenotype (Fig. 4A and B); > 80% of the cells expressed a high level of Foxp3, confirming that the enrichment protocol favored Treg expansion and prevented downregulation of Foxp3 (20, 52, 53). The cells were uniformly GITR+ (Fig. 4B), with minimal surface CTLA-4, but a high level of intracellular CTLA-4, another characteristic of conventional Treg (11). CD62L expression analysis revealed a mixed population with, on average, a majority (approx 60% of Foxp3+ cells) having down-regulated CD62L. This profile, associated with homogenous expression of CCR4 and minimal expression of CCR5, indicates that the majority of these T cells have the potential to migrate directly to peripheral tissues, a possible advantage for exhibition of their function (54). Significant fractions of the selected Foxp3+ cells expressed CD103 and Lag3, two molecules associated with powerful regulatory activity (55, 56). Moreover, almost all the cells were positive for CCR7, a molecule crucial for Treg migration to secondary lymphoid tissue and the control of the initiation of immune reactivity (57).

Figure 4
Phenotypic characterization of Treg obtained using the selection protocol

We next determined the suppressive capacity of the enriched Treg on CFSE-stained CD4 T cell proliferation induced by immature alloDC at a Treg:T cell ratio of 1:20, known to be ineffective when freshly-isolated Treg are employed (11, 58). As indicated in Fig. 5A, while freshly-isolated nTreg did not suppress the proliferation of alloreactive T cells at this ratio, the enriched Treg exerted a profound inhibitory effect. Since it has been clearly shown that, once activated, Treg exert profound non-specific function (59), we tested the suppressive activity of enriched Treg that were rested without DC for 2 days before their addition to cultures of CFSE-stained CD4 T cells and alloDC. Strong suppressive activity was still evident, even at a lower Treg:T cell ratio of 1:40 (Fig 5B). Moreover, we tested whether our enrichment protocol generated allo-Ag-specific Treg (AAsTreg). Treg (B10) were enriched against C3H DC and their ability to inhibit the proliferation of CFSE-stained T cells stimulated by either C3H or BALB/c (3rd party) DC was tested. Fig. 5C shows that the enriched Treg suppressed alloreactive T cell proliferation against C3H DC, but did not modulate the response to BALB/c DC. To rule out the existence of bias towards the chosen third party, the same experiment was repeated using (B10) Treg selected against BALB/c DC, followed by testing of their ability to suppress the response of CFSE-stained (B10) CD4 T cells against C3H-derived DC. The data, expressed as percentage of proliferating CD4 over the total CD4 T cells (Fig 5D) confirm the absence of non-specific suppression. Collectively, these results support the validity of the devised protocol for the enrichment of AAsTreg.

Figure 5
Co-culture of Treg and alloDC in the presence of MLRsup enriches for AAsTreg

Rapa administration creates an environment conducive to AAsTreg function

As we aimed to use AAsTreg post-operatively without irradiation or (selective) lymphodepletion, three important points needed to be addressed: a) suppression of acute graft rejection during AAsTreg enrichment, b) induction of an environment favorable to AAsTreg function, c) minimal manipulation of the recipient. To address these requirements, we first tested the capacity of a short, post-operative course of low dose Rapa (1mg/kg i.p. daily) to prevent heart graft infiltration by CD4+ and CD8+ T cells on day 7 post-transplant. As expected, significant reduction (10-fold), especially in CD8+ T cells by Rapa was observed (unpublished data). We then investigated the influence of Rapa administration on host peripheral T cells. To this end, it was important to distinguish the direct effects of systemic Rapa administration from those related to the presence of Rapa during Ag exposure (the transplanted organ). Naïve B10 mice were treated for 8 days with the 1mg/kg Rapa, euthanized, and the absolute numbers and incidence of CD8+, CD4+, and Foxp3+ T cells quantified in different tissues. As expected, Rapa administration to otherwise unmanipulated mice significantly reduced (almost 2- fold) the total number of circulating lymphocytes (unpublished data). This decrease was associated with thymic involution, that correlated with a compromised transition of thymocytes from single-positive to double-positive and consequent reduced thymic output. Surprisingly, the frequency of Foxp3+ cells in the blood dropped from 6.3 ± 0.9% to 2.7 ± 0.3% of CD4+ T cells. A similar decrease was observed in the spleen,- from 16.3 ± 0.6% to 10.2 ± 1.4% (unpublished data).

Rapa treatment of heart graft recipients for 8 days post transplant markedly affected the cellularity of secondary lymphoid tissue (Table 1). As expected, Rapa prevented the increase in absolute numbers of both lymph node and spleen cells observed in untreated graft recipients. In addition, a generalized reduction (2.3-fold in lymph node and 1.3-fold in spleen) in absolute lymphocyte numbers was evident in comparison to normal animals, and the proportion of CD4+ T cells was decreased. This latter effect was particularly evident in the spleen,- the principal lymphoid tissue draining the transplant. Moreover, although the unexpected decrease in frequency of Foxp3+ cells was still evident in the blood, there was a marked increase in the proportion of CD4+Foxp3+ T cells in the spleens of Rapa-treated graft recipients compared with untreated hosts (Table 1). These results confirmed that, in addition to preventing alloreactive T cell expansion, Rapa reduced the absolute number of lymphocytes in lymphoid tissues, thus creating an environment that would favor Treg activity as the T:Treg balance was significantly altered. This balance was also altered by the capacity of Rapa to favor the accumulation (or induction) of Treg in the lymphoid tissue draining the graft.

Table I
Influence of Rapa administration on T lymphocytes.

APC maturation reduces T cell sensitivity to AAsTreg,- dependence on IL-6

Maturation of APC, and DC in particular, in response to danger signals is associated with the release of multiple soluble factors (IL-6 and other, still unidentified molecules) that, when all present at the same time, can render conventional T cells refractory to Treg suppression. Organ transplantation is associated with a potent inflammatory response caused by the release of danger signals that induce APC maturation (24). We speculated that modulation of alloreactive T cell susceptibility to suppression, due to exposure to this cocktail of pro-inflammatory cytokines, could affect the therapeutic efficacy of AAsTreg. Additionally, all reports investigating inflammation-induced T cell refractoriness to Treg suppression (22, 60) have used anti-CD3 mAb as the stimulatory agent, and no information exists relating to the Ag specificity of this effect. We investigated whether AAsTreg were as susceptible as freshly-isolated Treg in their ability to control alloreactive T cells stimulated by maturing APC. CD4+CD25 T cells were stimulated with allogeneic, immature or LPS-exposed DC, and T cell proliferation measured after 3 days by 3H-thymidine incorporation. The suppressive capacity of AAsTreg added at two different AAsTreg:T cell ratios (1:20 and 1:40) was then measured and compared to that of freshly-isolated Treg (at 1:4 ratio). T cells stimulated by immature DC were strongly suppressed by either AAsTreg in a dose-related manner or fresh Treg (Fig 6A, and unpublished data). As expected, fresh Treg did not affect T cell proliferation induced by mature DC (Fig 6B). Surprisingly, AAsTreg exerted a reduced but significant suppressive effect at a 1:20 ratio. However, the extent of suppression was not equivalent to that exerted on immature DC-stimulated T cells (Fig 6A), and suppression at the 1:40 ratio was completely abolished. This confirmed that APC maturation favors T cell activation by reducing their sensitivity to Treg regulation, even in the context of allo-Ag-specific reactivity.

Figure 6
AAsTreg are potent suppressors of alloreactive T cells but susceptible to IL-6-dependent modulation of their suppressive activity by maturing DC

As Treg proliferative capacity is highly influenced by cytokines (58), we questioned whether the regulation of suppression observed by measuring 3H-thymidine incorporation was truly associated with T cell proliferation. Thus, the above experiment was repeated using CFSE-stained CD4 T cells and the indicated ratios of AAsTreg. The CFSE dilution profile measured after 4 days of co-culture indicated that AAsTreg significantly suppressed T cell proliferation when immature DC were used as the stimulators (Fig 6C). However, when mature DC where used, alloreactive T cell proliferation was restored, confirming the results obtained with thymidine incorporation. Additionally, as indicated previously, this effect was dependent on the release of multiple pro-inflammatory cytokines, the precise identity of which remains unclear, but certainly includes IL-6. Indeed, as all the components of the cocktail must be present at the same time to exert an effect (22), when mature IL-6−/− DC were used as stimulators (Fig 6D), alloreactive T cells remained susceptible to AAsTreg (and freshly-isolated Treg)-mediated suppression, and to the same extent as T cells stimulated by immature DC.

DC from Rapa-treated mice show marked reduction in IL-6 production

The above results clearly indicated that even though AAsTreg showed stronger regulatory capacity than nTreg, their function could still be affected significantly by the release of proinflammatory cytokines by APC. We next tested whether Rapa could also exert anti-inflammatory activity that could (additionally) support the pro-tolerogenic activity of AAsTreg. B10 mice were treated with the DC poietin Flt3L for 10 days to markedly increase DC (37). During the last 7 days, Rapa was administered using the same regimen as for transplant recipients. On day 10, the animals were euthanized, splenic DC isolated and stimulated ex-vivo with the TLR4 ligand LPS. After overnight incubation, the amount of IL-6 released in the supernatant was quantified. As indicated in Fig 6E, DC isolated from Rapa-treated animals released 3-fold less IL-6. This result indicated that Rapa would promote graft survival by inducing an environment that supports Treg activity.

AlloAg-specific Treg promote indefinite graft survival, associated with anergy of donor-reactive T cells

Using the above insights, we devised the therapeutic protocol depicted in Fig. 7A and tested its efficacy. Heart graft survival data shown in Fig 7B, and summarized in Fig 7C, indicate that, in comparison to the untreated control group (median survival time [MST]=11d), Rapa alone (d 0–9) significantly inhibited rejection (MST=30d), but with no long-term survivors (LTS). By contrast, infusion of AAsTreg to Rapa-treated mice on d 7 post-transplant, resulted in long-term survival in > 80% of graft recipients (MST>150d). The addition of freshly-isolated Treg (polyTreg) prolonged graft survival (MST=45), but only 40% of the grafts survived long-term. These results confirmed that AAsTreg possess an inherent advantage in vivo over non-selected nTreg. Heart grafts in recipients treated with Rapa and Treg selected against 3rd party (C3H) Ags (Fig 7B) survived a similar length of time to those in the Rapa-only group (and with an inferior MST to those in the polyTreg-treated group).

Figure 7
Combined post-transplant AAsTreg and Rapa administration promotes long-term (>150 d) alloAg-specific heart graft survival

We also investigated the cellular mechanisms responsible for the long-term maintenance of the allografts. LTS (>150d) were euthanized and the frequency of Foxp3+ CD4 T cells analyzed (Fig 8A). In comparison to age-matched controls (normal B10), the two LTS analyzed showed a 2-fold increase in the frequency of Treg in the spleen. This suggested that long-term graft acceptance was associated with sustained Treg activity. We then tested the reactivity of bulk CD4 T cells isolated from the spleens of the two LTS against donor-derived DC (Fig 8B). LTS showed a significant reduction (1.8-fold on average) in T cell proliferation. However, removal of CD25+ T cells from the tested cells did not compensate for the difference in responsiveness between LTS and control T cells, as a 2-fold difference was maintained. This result called into question the role of Treg in long-term maintenance of graft survival, even though these findings do not rule out a protective effect of the Treg mediated within the transplanted tissue (61, 62). Interestingly, addition of exogenous IL-2 to the assay with CD4+CD25 T cell responders caused an almost complete restoration of responsiveness, with no significant difference between the groups. This suggests that AAsTreg + Rapa created conditions that favored induction of an anergic state in alloreactive T cells, that permitted long-term allograft survival (without relying on the suppressive function of endogenous or exogenous Treg).

Figure 8
Long-term surviving graft recipients exhibit a high frequency of Foxp3+ cells, but Treg-independent alloreactive T cell hypo-responsiveness


Our data and others’ (47, 58) indicate that co-incubation of freshly-isolated Treg with donor-derived DC can expand potent allo-Ag-specific Treg. This was demonstrated in the present study by comparison of the transplant survival curves for donor-selected AAsTreg-infused recipients and those given third-party-selected AAsTreg (Fig. 7B). Graft MST in the latter group was equivalent to that of animals treated with Rapa only, indicating that the injected Treg were unable to regulate the response to third party. This observation draws attention to graft survival in recipients given non-selected (poly)-Treg, with a MST of 45d. Multiple data, including ours (Fig 1), suggest that, as the T cell pool comprises a high frequency of alloreactive cells, the repertoire of Treg is similarly represented. This could explain the development of 40% LTS in the poly-Treg-treated group, together with the level of success achieved in early pre-clinical studies using polyclonally-expanded Treg to promote BM transplant acceptance and prevention of graft-versus-host disease (5, 6). The significant increase in frequency of LTS following injection of AAsTreg underscores how delicate the balance between tolerance and reactivity may be, and also that the Ag-specific enrichment protocol may be crucial for the successful clinical application of such therapy.

Our observations made during development of the enrichment protocol underscore DC maturation as a key variable relevant to the successful therapeutic application of Treg. Recent reports (47) have indicated that mature DC (CD86hi) have a stronger Treg stimulatory capacity than immature DC. Our data agree with this finding, but also urge caution in the use of mature DC to overcome the in vitro anergic state of Treg. We show clearly that, following Treg co-culture with allogeneic mature DC, a significant proportion of Foxp3 cells accumulates in culture. The majority of these Foxp3 cells are TH17 cells (63). This result is not unexpected (64), although not reported by Yamazaki et al (47). The main reason for these discordant findings is probably the different Treg purification methods used in each study. Magnetic bead-mediated isolation does not guarantee the same level of purity as flow sorting, but it is fast becoming the strategy of choice for clinical-grade Treg purification. Maturing DC release a cocktail of factors (the composition of which remains undefined, besides identification of the necessary, but insufficient, role of IL-6) that renders T cells less susceptible to Treg suppression (22). This could result in the release of small numbers of contaminating cells from Treg-mediated suppression and permit their faster proliferation and differentiation toward A TH17 phenotype. This hypothesis was tested in a preliminary experiment in which we added CFSE-stained CD4+CD25 to the isolated CD4+CD25+ (Treg), cultured them with mature DC, and analyzed their CFSE dilution profile after 5 d (unpublished data). Differently from the pool of CD4+CD25+ cells, CD4+CD25 cells did not proliferate significantly. This indicated that, under the conditions tested, Treg could still control the expansion of naïve T cells, and suggested that TH17 cells were expanding from the original pool of CD4+CD25+ T cells. This result is in accordance with a recent study (53) that used Foxp3-restricted GFP expression to show that, following activation in the presence of IL-6, a significant proportion of Treg converted to Foxp3IL-17+ TH17 cells. This phenomenon requires further in-depth analysis that is beyond the scope of the present investigation. Despite the fact that such data could reduce the positive impact of the proposed methodology, they underscore the need for caution in translation of Treg-based therapies to the clinic. Compared with rodents, human Treg isolation is more difficult, even though useful surface markers have been identified (32, 33, 35). This could render the process of human Ag-specific Treg selection susceptible to the expansion of potentially harmful effector T cells (48) if appropriate protocols are not implemented to prevent DC maturation.

These findings prompted us to develop an AAsTreg selection protocol based on immature DC. In conventional MLR, Treg proliferate extensively (Fig. 1B), suggesting that the supernatant (MLRsup) contains specific factors that support the activation and expansion of AAsTreg. Additionally, it has been reported that IL-2 supports Treg expansion (58). As the use of a single cytokine would facilitate translation of the protocol to the clinical setting, we compared the influence of MLRsup or IL-2 addition to co-cultures of Treg and immature donor DC. Both methods improved the expansion of Treg significantly, while minimizing TH17 cell expansion. Co-culture with added IL-2, however, resulted in significant Foxp3 cell proliferation. These cells were not IL-17+. Two hypotheses can be formulated regarding the identity of these cells. It is possible that they are derived from a small fraction of contaminating cells released from Treg control by the addition of large amounts of exogenous IL-2. Adding back a small number of CFSE-stained CD4+CD25 cells to Treg before the co-culture, excluded this possibility, as no significant proliferation was evident (unpublished data). Alternatively, these Foxp3 cells could derive from Treg that have lost Foxp3 expression. Foxp3 expression is highly regulated and influenced by many external factors, including cytokines such as TGF-β1, IL-2, IL-4, IL- 7, and IL-15. Our Luminex™-based quantification of the cytokines present in the MLRsup did not single out specific factor(s) responsible for sustaining Foxp3 expression. Interestingly, high levels of IL-13 were revealed in the MLRsup, but conflicting, and only indirect evidence exists regarding its role in Treg and Foxp3 expression (6569). Based on these observations, further investigations are necessary to identify specific factor(s) that could be used as an alternative to MLRsup. Recent reports have documented the loss of suppressive capacity in Treg with ablation of Foxp3 expression (7072). This raises doubt over the use of a selection protocol that does not support Foxp3 expression. Conversely, MLRsup sustained consistently high levels of Foxp3 expression, favoring its use for AAsTreg enrichment.

The short course of Rapa given to graft recipients shifted the effector T cell:Treg ratio in favor of the latter. It is recognized that immunosuppressive agents affect intrathymic selection of new T cells. At the dose tested, Rapa caused a 2-fold reduction in the absolute number of peripheral T cells. This probably resulted from a combination of highly-reduced thymic output and minimized homeostatic proliferation of circulating T cells. The influence of Rapa on the proportion of Treg among T cells is noteworthy. In the absence of antigenic stimulation, Rapa reduced the percentage of circulating Foxp3+ cells. When Ag stimulation was present (in the form of a heart allograft), the proportion of Foxp3+ cells increased significantly. Three non-exclusive properties of Rapa could account for this observation. First, Rapa promotes activation-induced cell death of effector T cells, while sparing Treg (31). Second, while Rapa prevents expansion of effector T cells, it allows proliferation of Treg (6, 29). Third, Rapa has been reported to promote the expression of Foxp3 (31, 73) and that could contribute to the alterations in proportions of Foxp3+ and Foxp3 cells we observed. On the whole, these changes are conducive to an effector T cell:Treg ratio that promotes the activity of the latter, even though it does not ultimately prevent graft rejection (Rapa only group; Fig 7).

The innate immune response converts T cells to a state refractory to Treg suppression (60, 74). This indicates that Treg transfer into a patient could elicit no effect if the recipient T cells are no longer sensitive to Treg control. Although there is evidence that exogenous danger signals can break an established Treg-dependent tolerant state (24), no information exists on the role of this phenomenon in regulation of Ag-specific responses and alloreactivity, in particular. Our data clearly indicate that, although AAsTreg are more effective than polyclonal Treg in suppressing alloreactive T cells, they remain susceptible to the capacity of maturing DC to promote a Treg-independent T cell response. As indicated by Pasare et al (22), this effect remains strictly dependent on the secretion of multiple cytokines. We observed that the absence of IL-6 (so far, the only cytokine shown to be a necessary, albeit insufficient, component of the cocktail) from the system allowed recovery of T cell susceptibility to AAsTreg suppression. Our observation that DC isolated from Rapa-treated animals released significantly lower levels of IL-6 following maturation indicates that Rapa can also support the function of Treg by reducing inflammation. Such activity is underscored by the effects on graft survival. All these properties point to Rapa as a unique drug that favors the balance of the immune system toward regulation.

Long-term graft survival (>150 days) was achieved by combining Rapa and AAsTreg. This raised the question of the extent and duration of the activity associated with AAsTreg. Analysis of T cell reactivity in LTS indicated that, at 200d post-transplant, Treg (both endogenous and exogenous) did not play a dominant role in controlling T cell activation in the spleen and lymph nodes. Although we cannot exclude a dominant, sustained role of Treg within the graft (61, 62), our data can be interpreted using the following model: combination of Rapa and AAsTreg permits transitory control of the alloimmune response, that is probably associated with partial elimination of the reactive T cells and conversion of the remaining cells to an anergic state. Persistence of Ag sustains a tolerant state (75, 76), that is dependent on the maintenance of circulating alloreactive T cells in a state of anergy. We must emphasize, however, that long-term survival was unexpected. The Treg selection process was directed towards those cells activated via the direct pathway of Ag recognition/presentation. These cells were then able to control directly alloreactive T cells, but not indirectly-activated cells. Our protocol targeted the indirect pathway of T cell activation only for the initial 10 days post-transplant (due to Rapa administration). In fact, histological analysis of LTS revealed cellular infiltration and graft tissue damage, suggesting a slowly progressive immune response (unpublished data). Such a response does not result in cessation of graft function, as indicated recently by Joffre et al (17). This underscores the need to develop a selection process for AAsTreg that are activated through the indirect pathway. Although it demonstrates the relevance of the spectrum of specificity of Treg to generate a therapeutic effect, the method proposed by Joffre et al is unfortunately not applicable to clinical settings, as it requires F1-derived APCs. However, other approaches have been delineated in the literature to select Treg with indirect specificity (77, 78).

In summary, we provide strong evidence of the existence of key molecular and cellular variables that significantly impact the successful application of experimental Treg therapy. While further investigations are necessary to better characterize these variables, the results obtained underscore the potential advantage of the devised approach. As the number of Treg required for therapeutic efficacy remains a major consideration for their clinical application, having identified parameters that can be targeted to strengthen (or preserve) their function permits the use of a much lower number in comparison to what is required by other approaches (17, 20). The present approach overcomes concern over the use of Treg generated by genetic modification (forced expression of Foxp3) (79, 80), as the long-term safety of such an approach has not yet been demonstrated. Additionally, our protocol is compatible with conventional immunosuppression. More importantly, this approach results in long-term alloAg-specific graft survival, a fundamental goal in the design of improved therapies.


We thank Derek Barclay for conducting Luminex™-based quantifications on our samples. We thank our colleagues for constructive critiques of the manuscript and Miriam Freeman for excellent administrative support. We are grateful to Dr Hongmei Chen and the Starzl Transplantation Institute flow cytometry core facility for expert advice and assistance.


This is an author-produced version of a manuscript accepted for publication in The Journal of Immunology (The JI). The American Association of Immunologists, Inc. (AAI), publisher of The JI, holds the copyright to this manuscript. This version of the manuscript has not yet been copyedited or subjected to editorial proofreading by The JI; hence, it may differ from the final version published in The JI (online and in print). AAI (The JI) is not liable for errors or omissions in this author-produced version of the manuscript or in any version derived from it by the U.S. National Institutes of Health or any other third party. The final, citable version of record can be found at

1This work was supported by a Transplantation Society Research Fellowship and a non-concurrent American Heart Association Beginning Grant-in-Aid, a Starzl Transplantation Institute Young Investigator Award and a Joseph A. Patrick Research Fellowship in Transplantation (to G.R.) and by National Institutes of Health grants R01 AI067541 and R01 AI060994 (to A.W.T.). Yoram Vodovotz was supported in part by the National Institutes of Health grants P50-GM-53789 and R33-HL-089082 as well as grants from the Commonwealth of Pennsylvania and the Pittsburgh Lifesciences Greenhouse. TSL is the recipient of an American Society of Transplantation Basic Science Fellowship. BMM is supported by NIH institutional training grant T32 AI74490.

3Abbreviations used in this paper:

Treg, regulatory T cells;

mTOR, mammalian target of rapamycin;

DC, dendritic cells;

AAsTreg, allo-antigen specific Treg;

Rapa, rapamycin;

MLRsup, supernatant of MLR;

LTS, long-term survivor;

MST, median survival time.


1. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation--how much of the promise has been realized? Nat Med. 2005;11:605–613. [PubMed]
2. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7:610–621. [PubMed]
3. Cobbold SP, Adams E, Graca L, Daley S, Yates S, Paterson A, Robertson NJ, Nolan KF, Fairchild PJ, Waldmann H. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev. 2006;213:239–255. [PubMed]
4. Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant. 2007;7:1457–1463. [PubMed]
5. Schiopu A, Wood KJ. Regulatory T cells: hypes and limitations. Current opinion in organ transplantation. 2008;13:333–338. [PubMed]
6. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007;7:585–598. [PubMed]
7. Raimondi G, Turner MS, Thomson AW, Morel PA. Naturally occurring regulatory T cells: recent insights in health and disease. Critical reviews in immunology. 2007;27:61–95. [PubMed]
8. Chen ZK, Cobbold SP, Waldmann H, Metcalfe S. Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation. 1996;62:1200–1206. [PubMed]
9. Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med. 1990;171:141–157. [PMC free article] [PubMed]
10. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3:199–210. [PubMed]
11. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–787. [PubMed]
12. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006;212:256–271. [PubMed]
13. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239–244. [PMC free article] [PubMed]
14. Racusen LC. T-regulatory cells in human transplantation. Am J Transplant. 2008;8:1359–1360. [PubMed]
15. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol. 2005;5:343–349. [PubMed]
16. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood. 2007;109:827–835. [PubMed]
17. Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P, van Meerwijk JP. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nature medicine. 2008;14:88–92. [PMC free article] [PubMed]
18. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, June CH, Serody JS, Blazar BR. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804–3812. [PubMed]
19. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001;166:3789–3796. [PubMed]
20. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am J Transplant. 2008;8:298–306. [PubMed]
21. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol. 2003;3:147–158. [PubMed]
22. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299:1033–1036. [PubMed]
23. Walker LS. Regulatory T cells overturned: the effectors fight back. Immunology. 2009;126:466–474. [PubMed]
24. Alegre ML, Goldstein DR, Chong AS. Toll-like receptor signaling in transplantation. Current opinion in organ transplantation. 2008;13:358–365. [PMC free article] [PubMed]
25. Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation. 1998;66:1387–1388. [PubMed]
26. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9:324–337. [PMC free article] [PubMed]
27. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, Strom TB, Turka LA. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nature medicine. 1999;5:1303–1307. [PubMed]
28. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111:453–462. [PubMed]
29. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol. 2008;180:5794–5798. [PMC free article] [PubMed]
30. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105:4743–4748. [PubMed]
31. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007;7:1722–1732. [PMC free article] [PubMed]
32. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701–1711. [PMC free article] [PubMed]
33. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203:1693–1700. [PMC free article] [PubMed]
34. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178:7018–7031. [PubMed]
35. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol. 2006;176:2808–2816. [PubMed]
36. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184:1953–1962. [PMC free article] [PubMed]
37. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7:610–621. [PubMed]
38. Coates PT, Barratt-Boyes SM, Zhang L, Donnenberg VS, O'Connell PJ, Logar AJ, Duncan FJ, Murphey-Corb M, Donnenberg AD, Morelli AE, Maliszewski CR, Thomson AW. Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand. Blood. 2003;102:2513–2521. [PubMed]
39. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005;5:228–236. [PubMed]
40. Lathrop SK, Santacruz NA, Pham D, Luo J, Hsieh CS. Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med. 2008;205:3105–3117. [PMC free article] [PubMed]
41. Fazilleau N, Bachelez H, Gougeon ML, Viguier M. Cutting edge: size and diversity of CD4+CD25high Foxp3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+CD25− T cells. J Immunol. 2007;179:3412–3416. [PubMed]
42. Wong J, Obst R, Correia-Neves M, Losyev G, Mathis D, Benoist C. Adaptation of TCR repertoires to self-peptides in regulatory and nonregulatory CD4+ T cells. J Immunol. 2007;178:7032–7041. [PubMed]
43. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, Chatila TA. Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol. 2007;178:2961–2972. [PubMed]
44. Hsieh CS, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity. 2004;21:267–277. [PubMed]
45. Larkin J, 3rd, Picca CC, Caton AJ. Activation of CD4+ CD25+ regulatory T cell suppressor function by analogs of the selecting peptide. Eur J Immunol. 2007;37:139–146. [PubMed]
46. Koehn B, Gangappa S, Miller JD, Ahmed R, Larsen CP. Patients, pathogens, and protective immunity: the relevance of virus-induced alloreactivity in transplantation. J Immunol. 2006;176:2691–2696. [PubMed]
47. Yamazaki S, Patel M, Harper A, Bonito A, Fukuyama H, Pack M, Tarbell KV, Talmor M, Ravetch JV, Inaba K, Steinman RM. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A. 2006;103:2758–2763. [PubMed]
48. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrej B, Donnarumma M, Habicht A, Clarkson MR, CIacomini J, Glimcher LH, Sayegh MH, Ansari MJ. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med. 2008;205:3133–3144. [PMC free article] [PubMed]
49. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008;453:1051–1057. [PubMed]
50. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 2007;8:457–462. [PubMed]
51. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10:1000–1007. [PMC free article] [PubMed]
52. Horwitz DA, Zheng SG, Wang J, Gray JD. Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3+CD4+ Treg. Eur J Immunol. 2008;38:912–915. [PubMed]
53. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: regulatory T cells induce CD4+CD25−Foxp3− T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol. 2007;178:6725–6729. [PubMed]
54. Zhang N, Schroppel B, Lal G, Jakubzick C, Mao X, Chen D, Yin N, Jessberger R, Ochando JC, Ding Y, Bromberg JS. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity. 2009;30:458–469. [PMC free article] [PubMed]
55. Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, Feuerer M, Debes GF, Lauber J, Frey O, Przybylski GK, Niesner U, de la Rosa M, Schmidt CA, Brauer R, Buer J, Scheffold A, Hamann A. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med. 2004;199:303–313. [PMC free article] [PubMed]
56. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503–513. [PubMed]
57. Chen D, Bromberg JS. T regulatory cells and migration. Am J Transplant. 2006;6:1518–1523. [PubMed]
58. Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol. 2006;18:103–110. [PubMed]
59. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389–400. [PubMed]
60. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Backstrom BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nature medicine. 2007;13:423–431. [PMC free article] [PubMed]
61. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med. 2002;195:1641–1646. [PMC free article] [PubMed]
62. Sawitzki B, Lehmann M, Ritter T, Graser E, Kupiec-Weglinski JW, Volk HD. Regulatory tolerance-mediating T cells in transplantation tolerance. Transplant Proc. 2001;33:2092–2093. [PubMed]
63. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–852. [PubMed]
64. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–189. [PubMed]
65. Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, Talor MV, Baldeviano GC, Frisancho S, Gabrielson K, Bedja D, Rose NR. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. The American journal of pathology. 2008;172:1195–1208. [PubMed]
66. Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, Fukada SY, Liu FT, Liew FY, Lukic ML. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol. 2009;182:1167–1173. [PubMed]
67. Joetham A, Matsubara S, Okamoto M, Takeda K, Miyahara N, Dakhama A, Gelfand EW. Plasticity of regulatory T cells: subversion of suppressive function and conversion to enhancement of lung allergic responses. J Immunol. 2008;180:7117–7124. [PubMed]
68. Sinha S, Kaler LJ, Proctor TM, Teuscher C, Vandenbark AA, Offner H. IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. J Immunol. 2008;180:2679–2685. [PMC free article] [PubMed]
69. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25−CD4+ precursors. J Immunol. 2005;175:6107–6116. [PubMed]
70. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol. 2007;8:277–284. [PubMed]
71. Lin W, Haribhai D, Relland LM, Truong N, Carlson MR, Williams CB, Chatila TA. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol. 2007;8:359–368. [PubMed]
72. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007;445:766–770. [PubMed]
73. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:7797–7802. [PubMed]
74. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity. 2004;21:733–741. [PubMed]
75. Raimondi G, Zanoni I, Citterio S, Ricciardi-Castagnoli P, Granucci F. Induction of peripheral T cell tolerance by antigen-presenting B cells. II. Chronic antigen presentation overrules antigen-presenting B cell activation. J Immunol. 2006;176:4021–4028. [PubMed]
76. Raimondi G, Zanoni I, Citterio S, Ricciardi-Castagnoli P, Granucci F. Induction of peripheral T cell tolerance by antigen-presenting B cells. I. Relevance of antigen presentation persistence. J Immunol. 2006;176:4012–4020. [PubMed]
77. Tsang JY, Tanriver Y, Jiang S, Xue SA, Ratnasothy K, Chen D, Stauss HJ, Bucy RP, Lombardi G, Lechler R. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest. 2008;118:3619–3628. [PMC free article] [PubMed]
78. Jiang S, Tsang J, Game DS, Stevenson S, Lombardi G, Lechler RI. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance. Transplantation. 2006;82:1738–1743. [PubMed]
79. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev. 2008;223:371–390. [PubMed]
80. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007;110:2983–2990. [PubMed]